{"Clinical Trial ID": "NCT00193206", "Intervention": ["INTERVENTION 1:", "Intervention", "Systemic therapy", "ABI-007: ABI-007 175 mg/m2 D1 q 14 days x 6 cycles", "Epirubicin: Epirubicin 50 mg/m2 D1 q 14 days x 6 cycles", "Gemcitabine: Gemcitabine 2000 mg/m2 IV D1 q 14 days x 6 cycles"], "Eligibility": ["Incorporation criteria:", "To be included in this study, you must meet the following criteria:", "Locally advanced / Inflammatory breast adenocarcinoma", "- 18 years or older", "Normal heart function", "\u2022 Capable of carrying out activities of daily life with minimum assistance", "No previous chemotherapy for breast cancer", "\u2022 Sensitivity of bone marrow, liver and kidneys", "No evidence or history of significant cardiovascular abnormalities", "A sentinel knot or axillary dissection", "Sign an Informed Consent Form", "- Exclusion criteria:", "You may not participate in this study if any of the following applies to you:", "Maternal or maternal breast-feeding", "\u2022 History of heart disease with congestive heart failure", "\u2022 Heart attack in the previous 6 months", "\u2022 Prior chemotherapy or hormone therapy for breast cancer", "\u2022 History of uncontrolled active infection", "Note: There are other inclusion and exclusion criteria. The study centre will determine if you meet all the criteria. If you are not eligible for the trial, the study staff will explain the reasons. If you are eligible, the study staff will explain the trial in detail and answer any questions you may have."], "Results": ["Performance measures:", "Complete pathological response", "For the purposes of this study, a complete pathological response (CPR) was not defined as a residual invasive tumour in the breast (pT0) and axillary lymph nodes (pN0), raw or microscopic, in the sample taken at the time of surgical resection.", "Time limit: 18 months", "Results 1:", "Title of the arm/group: Intervention", "Description of the arm/group: Systemic therapy", "ABI-007: ABI-007 175 mg/m2 D1 q 14 days x 6 cycles", "Epirubicin: Epirubicin 50 mg/m2 D1 q 14 days x 6 cycles", "Gemcitabine: Gemcitabine 2000 mg/m2 IV D1 q 14 days x 6 cycles", "Total number of participants analysed: 116", "Type of measure: Number of participants", "Unit of measure: Participants 23 19.8%"], "Adverse Events": ["Undesirable Events 1:", "Total: 22/123 (17.89%)", "Ischaemic heart disease/infarction [1]1/123 (0.81%)", "Pain - Breast 2/123 (1.63%)", "Dehydration 2/123 (1.63%)", "Deaths [2]1/123 (0.81%)", "Weakness 1/123 (0.81%)", "Pain - Liver 1/123 (0.81%)", "Infection - Skin [3]3/123 (2.44%)", "gastrointestinal infection [4]1/123 (0.81%)", "Infection - Vein [5]2/123 (1.63%)", "Infection - Pneumonia 1/123 (0.81%)"]}